The comprehensive collaboration between the top Russian medical university and one of the world’s leading pharmaceutical companies will be aimed at implementing the Federal Target-Oriented Program “PHARMA 2020”. In the medium term, this program will contribute to developing the potential and improving the competitiveness of the Russian science. The joint activities will be organized as a part of establishing the Russian Science and Technology Park of Biomedicine at I.M. Sechenov First Moscow State Medical University. In the first year, the potential for cooperation will be 50 million rubles and, in the future, it may reach 1.5-5 billion rubles.
Nenad Pavletic, CEO of Roche in Russia, said, “We are aware of the need for active work to develop the Russian pharmaceutical industry and contemporary education of medical professionals and scientists. Including Russian research institutions in the global chain for creation of innovative medical products is a priority objective, and this is exactly what we will be working on together with the experts of I.M. Sechenov First Moscow State Medical University. Today, we are talking about the first Roche project on localizing R&D in Russia, which is intended to drive research activities in the area of pharmaceuticals and health care.”
The priorities for collaboration include joint fundamental and applied research, as well as clinical testing and quality assessments of health technologies used in the area of neurology and oncology.